Access of medication review for people living with dementia: An analysis of inequality using Swedish register data

INTRODUCTION This study examines medication reviews (MRs) among people living with dementia (PWD) in Sweden, focusing on frequency and factors influencing access. METHODS Using nationwide register data, all diagnosed PWD from 2010 to 2016 were assessed for MR receipt in 2015 and/or 2016. The analysis guided by the Andersen healthcare utilization framework, considered predisposing, enabling, and need‐based factors through multiple logistic regression. RESULTS The MR rate was 16% in 2015, 21% in 2016, and 30% across both years. Increased MR likelihood was linked to higher comorbidity (adjusted odds ratio [aOR] = 1.45, p = 0.00), polypharmacy (aOR = 1.55, p = 0.00), and residential care (aOR = 3.92, p = 0.00), while being married or cohabiting reduced (aOR = 0.80, p = 0.00) MR receipt. DISCUSSION Despite national guidelines recommending annual MRs since 2012, rates remain low, especially outside residential care. The findings highlight the need for more equitable MR access for all PWD, particularly those not in residential care. Highlights Only 16%–21% of people with dementia received a medication review in 2015–2016 in Sweden. Higher comorbidity, polypharmacy, and residential care increased likelihood of receiving a medication review. Being married or cohabiting lowered the chance of receiving a medication review. Education level and gender did not affect access to medication reviews.